The future of
TARGETED THERAPEUTICS.
Linkster Therapeutics raises the bar on in vivo antibody development to create precision medicines for the right target, the right tissue & the right patient.
unique.
Precision medicine holds promise of a healthier society and creates targeted therapies for serious and chronic diseases. However, some targeted therapies are more targeted than others. Often, patients are devastated by the absence of a therapy or experience incomplete cure.
For this reason, Linkster Therapeutics aims at transforming targeted therapy with translational antibody engineering in tissue and living organisms. In fact, our unique Flycode® platform profiles large pools of peptide barcoded antibodies in vitro, in vivo and in silico. As a result, we innovate pharmacology profiling and accelerate the development of antibody drugs to create the next generation of precision medicines.
For this reason, Linkster Therapeutics aims at transforming targeted therapy with translational antibody engineering in tissue and living organisms. In fact, our unique Flycode® platform profiles large pools of peptide barcoded antibodies in vitro, in vivo and in silico. As a result, we innovate pharmacology profiling and accelerate the development of antibody drugs to create the next generation of precision medicines.
transforming.
Antibody researchers in every laboratory worldwide are trying to translate potent in vitro candidates to the clinic, one at a time. This often fails because molecules are engineered in vitro and are only much later tested in vivo. As a result, a massive number of candidates is generated that accumulate poorly in target organs and enrich in off-target organs unexpectedly high.
Linkster Therapeutics removes this translational bottleneck with superior in vivo platform technology. Important for this transformation are our advanced targeting strategies for tissue-specific delivery. Also, we excel to create conformation-specific antibody candidates against cell surface targets such as GPCRs and SLC transporters. Key remains our translational antibody engineering technology based on Flycode® peptide barcodes. It allows us to remove unwanted events of drug penetration into unwanted tissues. And it translates antibody design into candidates with higher efficacy, better dosing windows and toxicity.
Linkster Therapeutics removes this translational bottleneck with superior in vivo platform technology. Important for this transformation are our advanced targeting strategies for tissue-specific delivery. Also, we excel to create conformation-specific antibody candidates against cell surface targets such as GPCRs and SLC transporters. Key remains our translational antibody engineering technology based on Flycode® peptide barcodes. It allows us to remove unwanted events of drug penetration into unwanted tissues. And it translates antibody design into candidates with higher efficacy, better dosing windows and toxicity.
